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INTRODUCTION
Gene therapy research relies on the use and optimization of safe 
nonreplicating viral vectors. The choice of the viral vector depends 
on the tropism of the virus and its ability to allow sustained ther-
apeutic gene expression in the target cells. A key challenge to be 
overcome when designing an efficient gene therapy approach for 
treating neurodegenerative disorders is access to the central ner-
vous system (CNS), which must be mediated by either crossing the 
blood–brain barrier or by direct administration into the CNS. Adeno-
associated virus of serotype 9 (AAV9) has become a preferred vector 
for CNS delivery, due to its increased ability to cross the blood–brain 
barrier compared to other AAV serotypes.1,2 Indeed, several studies 
have demonstrated successful reversal of the disease phenotype 
and prolonged survival in mouse models of spinal muscular atro-
phy and amyotrophic lateral sclerosis upon intravenous AAV9 deliv-
ery.3–5 However, complications from systemic delivery of AAV9 and 
its expression in non-CNS tissues such as liver and heart are likely 
barriers to their success in patient clinical trials.6–9 Delivery into the 
cerebrospinal fluid via intracerebroventricular route provides some 
protection against diffusion of the AAV9 vector to peripheral organs 
and more efficiently targets neurons and glia.10 Similarly, cisterna 
magna route of injection has been recently adopted as an alterna-
tive method for delivery into cerebrospinal fluid (CSF) which results 
in wide-spread gene delivery throughout the CNS11–16; however, the 
data regarding the therapeutic efficacy using this administration 
route in mouse models is sparse. The findings reported here aim to 
improve the therapeutic potential of the AAV vectors when target-
ing to the motor neurons and motor pathways within CNS.
We previously demonstrated that the delivery of scAAV9 express-
ing survival motor neuron (SMN, causative gene for spinal muscu-
lar atrophy) driven by human cytomegalovirus (CMV) promoter 
into neonatal mice fully rescues early lethality in mice.5 Using self-
complementary (sc) AAV9 ensures a faster rate of gene transcrip-
tion onset due to the double-stranded conformation of the genome 
unlike conventional recombinant AAVs.17 The CMV promoter is 
known to drive high levels of gene expression across both CNS 
and non-CNS tissues when used in AAV vectors, and is therefore 
not necessarily an ideal promoter to use for restricted CNS trans-
duction.10,18,19 Several neuronal promoter sequences, including 
 synapsin 1, CamkII, MeCP2, and Hb9 have been previously used to 
restrict gene expression to the spinal cord and brain using viral vec-
tors.20–26 Efficient gene expression in the motor neurons of lumbar 
spinal cord was achieved after intracerebroventricular injection of 
mice using AAV9 driven by synapsin 1.10,20 Hb9 is a motor neuron-
specific promoter whose activity has been well-established in the 
developing and postnatal spinal cord.27,28 In addition to motor neu-
rons, a subset of Hb9-positive spinal cord interneurons has also 
been reported.29 Two short regulatory sequences within the distal 
region of Hb9 promoter with a size of 313 and 125 base pairs have 
been identified as sufficient for targeting gene expression exclu-
sively to spinal cord in transgenic embryonic mice.30 While lentiviral 
vectors expressing Hb9 enhancer-driven green fluorescent protein 
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Current barriers to the use of adeno-associated virus serotype 9 (AAV9) in clinical trials for treating neurological disorders are its 
high expression in many off-target tissues such as liver and heart, and lack of cell specificity within the central nervous system 
(CNS) when using ubiquitous promoters such as human cytomegalovirus (CMV) or chicken-β-actin hybrid (CAG). To enhance 
targeting the transgene expression in CNS cells, self-complementary (sc) AAV9 vectors, scAAV9-GFP vectors carrying neuronal Hb9 
and synapsin 1, and nonspecific CMV and CAG promoters were constructed. We demonstrate that synapsin 1 and Hb9 promoters 
exclusively targeted neurons in vitro, although their strengths were up to 10-fold lower than that of CMV. In vivo analyses of mouse 
tissue after scAAV9-GFP vector delivery via the cisterna magna revealed a significant advantage of synapsin 1 promoter over both 
Hb9 variants in targeting neurons throughout the brain, since Hb9 promoters were driving gene expression mainly within the 
motor-related areas of the brain stem. In summary, this study demonstrates that cisterna magna administration is a safe alternative 
to intracranial or intracerebroventricular vector delivery route using scAAV9, and introduces a novel utility of the Hb9 promoter for 
the targeted gene expression for both in vivo and in vitro applications.
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(GFP) resulted in moderate gene transfer efficiencies after intrapa-
renchymal injection directly into the ventral horn of the lumbar spi-
nal cord,26 expression data from AAV vectors driven by Hb9 have not 
been reported.
In the present study, we sought to assess the neuron-targeting 
properties and transduction efficiencies of scAAV9-GFP vectors car-
rying the Hb9 promoter enhancer elements and synapsin 1 (SYN1) 
promoter after delivery of the virus into neonatal mice via the cis-
terna magna by comparing them to the ubiquitous promoters 
CMV and chicken-β-actin fused to CMV enhancer (CAG). Our results 
demonstrate the first account on the use of promoters of vary-
ing strengths and specificities in scAAV9-mediated reporter GFP 
expression after intra-CSF delivery via cisterna magna in mice. In 
addition, they highlight the novel applicability of the promoter Hb9 
in therapeutic gene transfer to areas of the brain stem.
ReSUlTS
Characterization of scAAV9-GFP vectors carrying neuronal 
promoters in spinal cord neurons in vitro
One of the challenges associated with constructing a transgene 
within scAAV genomes is their small cloning capacity. Despite this, 
several studies have demonstrated efficient neuronal targeting 
using a short ~400 bp SYN1 promoter sequence20,22,25 while Hb9 
promoter enhancer elements30 have never previously been tested 
in AAV delivery systems. In this study, we assessed the activities of 
SYN1 and Hb9 hybrid promoters in a side-by-side comparison to 
conventionally used CAG and CMV promoters, which are known 
for their high-level ubiquitous expression properties. Five scAAV9-
GFP virus stocks carrying different promoter elements including 
CMV, CAG, Hb9 enhancer composed of two minimal Hb9 promoter 
sequences (Hb9e), Hb9 enhancer fused to CMV minimal promoter 
(Hb9cmv) and SYN1 (Figure 1) were produced to high titers (up to 
3 × 1013 vg/ml). Spinal cord cultures purified from embryonic day 13 
(E13) mouse embryos, containing motor neurons and interneurons 
as well as glia, were transduced on day in vitro 2 and analyzed after 
7 days. Representative image fields of the transduced cells used 
in quantification analyses are shown in Figure 2a. Promoter activi-
ties were determined by two principal measures: (i) the percent-
age of GFP-positive cells (transduction efficiency; Figure 2b) and 
(ii) the fluorescence intensity of the GFP-positive cells (promoter 
strength; Figure 2c). Cells transduced with CMV and CAG viral vec-
tors resulted in the majority of the cells expressing GFP (97 and 82%, 
respectively), while the transduction with the viral vectors encoding 
neuronal promoter constructs Hb9cmv, SYN1, and Hb9e resulted in 
a lower proportion of GFP-positive cells (59, 58, and 19%, respec-
tively; Figure 2b). The Hb9e vector resulted in significantly lower 
(P < 0.0001) transduction levels than those with other promoters. 
Analysis of the GFP intensity signal in the transduced cells revealed 
that despite similarities between CAG and CMV promoters in cell-
targeting efficiencies, CAG promoter strength was almost threefold 
lower than that of CMV (Figure 2c). It was evident that in the case of 
Hb9, the short CMV minimal promoter significantly enhanced gene 
expression (P < 0.01). Interestingly, in this in vitro assay, SYN1 had 
a comparably low strength to Hb9e construct (~50 intensity units; 
Figure 2c), despite having achieved 58% average gene transfer effi-
ciency as demonstrated in Figure 2b.
Both synapsin 1 and Hb9 target neurons, but not astrocytes, in vitro
In order to confirm the specificity of the promoter elements constructed 
in this study, the cell types targeted by SYN1 and Hb9 promoters were 
analyzed by immunocytochemistry using cell-type specific markers. 
scAAV9-CMV and scAAV9-CAG transduction resulted in high trans-
duction efficiency within both neurons and astrocytes, visualized 
by staining with the pan-neuronal marker MAP2 and the astrocytic 
marker glial fibrillary acidic protein (GFAP), respectively (Figure 3a–d). 
Consistent with their neuronal origin, SYN1, Hb9cmv and Hb9e pro-
moters were driving strictly neuronal gene expression (Figure 3e–j), 
as determined by distinctive neuronal morphology and a lack of 
double-GFP/GFAP-positive cells. Surprisingly, transduction with 
Hb9cmv vector did not result in GFP expression in GFAP-positive or 
MAP2-negative cells, despite the presence of the CMV minimal pro-
moter normally associated with ubiquitous expression (Figure 3g–h). 
Immunostaining for motor neuron marker Islet-1 (Supplementary 
Figure S1) revealed that motor neurons were efficiently targeted by 
all promoter constructs, suggesting the utility of these vectors in in 
vitro applications when neuronal tropism is required.
Synapsin 1 promoter, but not Hb9, results in low to moderate 
targeting of gene expression to motor neurons of the spinal cord
In order to assess in vivo gene transfer applicability of SYN1 and Hb9 
promoters in comparison with the conventionally used CMV and 
CAG in scAAV9 vectors in vivo, postnatal day 1 wild-type mice (n = 
3 per group) were injected via the cisterna magna with 1 × 1010 viral 
genomes of five titer-matched scAAV9-GFP vectors harboring CMV, 
CAG, SYN1, Hb9cmv, and Hb9e promoter sequences. CNS tissue 
was paraformadehyde (PFA)-perfused and harvested for immuno-
histochemistry analyses at 3 weeks postinjection. Immunostaining 
Figure 1 Construction of scAAV-GFP plasmids with neuronal promoter/
enhancer elements. Schematic representation of the scAAV9 vectors 
utilized in this study. Promoter elements were polymerase chain reaction-
amplified from corresponding plasmids (see Materials and Methods), 
introducing appropriate restriction sites depicted in (a). The entire 
promoter fragments were cloned between MluI and EcoRI restriction 
sites and inserted into scAAV-GFP plasmid (b). A representative vector 
containing full CMV promoter is shown in (b).
Kb
Full CMV promoter GFP
CMV
CMV enh
Chicken β-actin
mp
Mlul EcoRl
Mlul EcoRl
Mlul EcoRl
Mlul EcoRlBgIll
Mlul EcoRlBgIll
Agel
CAG
SYN1
Hb9cmv
Hb9e
ColE1 origin 3566..4248
Left ITR 1..140
scAAV-CMV-GFP
466.1 bp
CMV promoter 253..909
EGFP 960..1679
PolyA 1683..1828
Right ITR 1850..1989
AmpR 2809..3468
0 200 400 600 800 1,000 1,200 1,400
a
b
3Gene delivery to CNS via cisterna magna using AAV9
V Lukashchuk et al.
Molecular Therapy — Methods & Clinical Development (2016) 15055Official journal of the American Society of Gene & Cell Therapy
of the spinal cord sections with anti-NeuN antibody has demon-
strated efficient CNS-targeting capacities of CMV, CAG, and SYN1 
but not Hb9cmv or Hb9e promoters when used at the same dose 
(Supplementary Figure S2; Figure 4). In the spinal cord, scAAV9-CMV-
GFP transduction resulted in the highest GFP-positive cell numbers 
and most intense fluorescence levels in both the lumbar and cervi-
cal regions (Figure 4a,i), while CAG and SYN1 were noticeably weaker 
promoters (Figure 4c,e—lumbar cord; k,m—cervical cord). Moreover, 
unlike CMV (Figure 4b,j), SYN1 targeted CGRP-positive motor neu-
rons within the lumbar spinal cord with lower efficiency (Figure 4f,h). 
Surprisingly, none of the ventral horn neurons of the animals treated 
with scAAV9-Hb9cmv and scAAV9-Hb9e expressed GFP (data not 
shown), although several GFP-positive interneurons (up to 10 per 
area) were detected within the dorsal horns of the lumbar spinal cord 
(Figure 4g).
Quantification of the GFP-positive cells in each region, from 
three spinal cord sections located approximately 250–300 µm apart 
(Figure 4o), revealed that indeed CMV promoter-driven expression 
resulted in significantly higher (P < 0.0001) relative GFP-positive 
numbers of cells within cervical spinal cord, but not within lum-
bar spinal cord, when compared to CAG and SYN1. Analysis of the 
CGRP-positive motor neurons within the cervical and lumbar spi-
nal cord (Figure 4p) determined a transduction efficiency of about 
80% for motor neurons in CMV-treated animals. Transduction with 
both scAAV9-CAG and scAAV9-SYN1 across the spinal cord resulted 
in a significantly lower proportions of GFP-positive/CGRP-positive 
motor neurons than with CMV. These findings demonstrate that the 
CMV promoter has a distinct advantage for spinal cord gene trans-
fer, particularly to motor neurons, over both SYN1 and CAG promot-
ers when the vectors are delivered intracisternally.
Cisterna magna delivery of scAAV9 virus allows efficient 
transduction throughout the mouse brain
Determining the areas of the brain targeted by various promoters 
can identify therapeutically relevant promoters for gene delivery 
to treat neurological disorders. Here, we analyzed four principal 
areas of the brain after transduction with CMV, CAG, SYN1, Hb9cmv, 
and Hb9e promoter-bearing scAAV9-GFP viral vectors delivered 
through cisterna magna: cerebellum, motor cortex, motor-related 
areas of the brain stem, and hippocampus (Figure 5; Supplementary 
Figure S3). Merged-view representative images of the brain sections 
immunostained with anti-NeuN and anti-GFP antibodies provided 
qualitative information about the overall distribution and the lev-
els of transgene expression. As expected, CMV and CAG were 
very efficient at targeting gene expression throughout the brain. 
SYN1 showed a uniform distribution of the GFP-positive neurons 
throughout the brain (Figure 5 and Supplementary Figure S3). 
Interestingly, Hb9cmv and Hb9e promoter constructs were driving 
GFP expression in the brain stem, with majority of the GFP-positive 
cells detected around the motor and sensory areas of the midbrain 
(Figure 5b). Upon a closer inspection, the areas positive for GFP in 
Hb9cmv-treated animals were identified as motor-related areas of 
pons such as tegmental reticular nucleus and midbrain reticular 
nucleus. We also observed high frequency of GFP-positive cells in 
sensory areas of midbrain including superior and inferior colliculi. 
Unlike Hb9cmv, Hb9e did not mediate expression in the sensory 
areas, but still showed expression predominantly within the periaq-
ueductal gray and tegmental areas, as seen in the  low-magnification 
image in the Supplementary Figure S3. All promoters except Hb9e 
were capable of driving GFP expression within the cerebellum, pre-
dominantly within the Purkinje cell layer (Figure 5a). Purkinje cells 
Figure 2 Activity of the promoter constructs in scAAV9-GFP in embryonic mouse spinal cord culture. Mixed spinal cord culture was established from 
E13 wild-type mouse spinal cords. Cells were transduced with indicated virus at 2 days in vitro and fixed at 7 days post-transduction. GFP-positive cell 
numbers and the fluorescence levels were quantified using automated InCell Developer software. For establishing statistical significance, one-way 
analysis of variance test was used with Tukey’s multiple comparison test; *P < 0.01, ****P < 0.0001. (a) Representative images used in quantification by 
InCell Developer software. (b) In vitro transduction efficiency of scAAV9-GFP constructs measured as a proportion of the GFP-positive cells/nuclei of 
the total Hoechst-positive nuclei. (c) Promoter activities were determined as fluorescence intensities. Y axis represents average grey levels measured 
in each GFP-positive cell normalized to background. Bar graphs represent mean ± SD (n = 3). Scale bar = 100 µm.
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were identified by a distinct branched morphology, with their cell 
bodies located at the edge of granular cell layer. Hippocampus (par-
ticularly neurons of the polymorph layer within the dentate gyrus) 
and cerebral cortices were efficiently transduced with scAAV9 vec-
tors carrying CMV, CAG, and SYN1 promoters, but were less effi-
ciently transduced by Hb9cmv and Hb9e (Figure 5c,d); however, 
several detected GFP-positive cells suggested these Hb9 promoter 
constructs may have gene expression capabilities in these areas 
when delivered at higher doses.
Quantification of the GFP-positive cells within the chosen brain 
regions revealed similarities between the targeting properties of 
CMV, CAG, and SYN1 promoters across all four areas (Figure 5e–h). 
Hb9cmv and Hb9e promoters were significantly less efficient in 
transduction across cortex, hippocampus, and cerebellum, when 
normalized and compared to CMV. However, their transduction 
efficiencies within the brain stem (motor-related areas of mid-
brain; Figure 5g) were similar to those observed in the CMV-treated 
animals.
In order to account for the cell-type differences between the two 
conventionally-used promoters CMV and CAG, proportions of glial 
cells positive for GFP were determined, as a percentages of the total 
GFP-positive cell numbers represented (Supplementary Figure S4). 
Interestingly, we noticed that the number of transduced glia 
increased with the further location of the CNS areas from the injec-
tion site, with the highest proportions of GFP-positive cells located 
within lumbar cord region in animals injected with CMV or CAG vec-
tors. GFP-positive glial cells were detected within the midbrain of 
Hb9cmv and Hb9e treated animals (Figure 5b, yellow arrow) and 
equaled 2.2 and 7.5%, respectively, and 8% within the motor cortex 
of Hb9cmv-treated animals, but were not included in the analysis 
presented in Supplementary Figure S4.
In summary, our study demonstrated that CMV, CAG and SYN1 
have a significant advantage over Hb9cmv and Hb9e promoter activ-
ities when used in scAAV9-GFP vector system for transducing CNS in 
all of the regions tested, apart from the brain stem. Importantly, we 
have identified selective specificity of Hb9 enhancer for the brain 
Figure 3 scAAV9-GFP carrying neuronal promoters transduce spinal cord neurons in vitro. Mixed spinal cord culture was established from E13 mouse 
embryos. Transduced spinal cord cells were fixed at 7 days post-transduction and processed for immunocytochemistry using antibodies against 
neuronal tubulin marker MAP2 (a, c, e, g, i) and astrocytic marker GFAP (b, d, f, h, j). GFP signal was autofluorescence. (a,b) CMV, (c,d) CAG, (e,f) SYN1, 
(g,h) Hb9cmv, (i,j) Hb9e. Insets in (a–c) correspond to cells indicated by a yellow arrow head. White arrow heads indicate GFP-negative GFAP-positive 
astrocytes. Scale bar = 20 µm.
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Figure 4 Intracerebrospinal fluid delivery via cisterna magna of scAAV9-GFP results in differential gene delivery efficiencies in the mouse spinal cord 
depending on the use of the promoter. Wild-type mice at postnatal day 1 were injected with different scAAV9 viral vectors at equal doses of 1 × 1010 
vg/g and sacrificed after 21 days post-transduction. Lumbar spinal cord (a–h) and cervical spinal cord (i–n) 25 μm sections were immunostained 
with anti-GFP and anti-NeuN (left set of panels) or anti-CGRP antibodies (right set of panels), as indicated. (a,b), (i,j)—CMV; (c,d), (k,l)—CAG; (e,f), (h), 
(m,n)—SYN1; (g)—Hb9cmv. For SYN1-transduced ventral horn, a representative field with GFP-negative CGRP-positive motor neurons (f, arrow) as well 
as a less frequently occurring GFP-positive CGRP-positive motor neuron (h; a higher magnification image of the GFP-positive motor neuron denoted 
by an arrowhead in panel f) are shown. (g) Representative image of Hb9cmv-treated animal demonstrates GFP-positive lumbar cord dorsal horn 
interneurons. Scale bar = 50 µm. In vivo transduction efficiency (o) was determined based on the total numbers of GFP-positive cells within three ventral 
horns of cervical and lumbar regions, and normalized to the average CMV numbers in the cervical spinal cord region. Percentage of the motor neurons 
double-positive for CGRP/GFP (p) demonstrate the efficiency of the motor neuron targeting within the spinal cord regions. Hb9cmv and Hb9e were 
omitted from the graphs (o,p) due to the lack of detectable GFP-positive fluorescence. The results were analyzed using two-way analysis of variance 
followed by Tukey’s test for multiple comparisons. **P < 0.01; ***P < 0.001; ****P < 0.0001. Bar graphs represent mean ± SD (n = 3).
GFP NeuN
Relative GFP transfer efficiency
****
**** ****
***
**
Cervical
1.5 100
80
60
40
20
0
1.0
0.5
R
el
at
ive
 G
FP
+
 
ce
ll 
nu
m
be
rs
%
 G
FP
+/
CG
RP
+ 
m
ot
or
 n
eu
ro
ns
0.0
Lumbar
GFP-positive motor neurons
Cervical Lumbar
CMV
CAG
SYN1
CMV
CAG
SYN1
Merged/Hoechst GFP CGRP Merged/Hoechst
a b
c d
e f
g h
i j
k l
m
o p
n
6Gene delivery to CNS via cisterna magna using AAV9
V Lukashchuk et al.
Molecular Therapy — Methods & Clinical Development (2016) 15055 Official journal of the American Society of Gene & Cell Therapy
Figure 5 GFP expression in the brain following cisterna magna delivery of scAAV9-GFP vectors with different promoters. 40-µm brain sections of 
3-week-old transduced and PFA-perfused mice were immunostained with anti-GFP and anti-NeuN antibodies (b–d), or with anti-GFP antibodies 
alone (a) for NeuN-negative Purkinje neurons of the cerebellum (Hb9e treatment shown with anti-GFP antibody staining only, to avoid masking the 
weak GFP signal). Representative images were captured on the sections of cerebellum (a), brain stem (midbrain, motor-related; b), hippocampus 
(dentate gyrus—polymorph layer; c), and motor cortex (d). Yellow arrow heads point to NeuN-negative glial cells used in quantification (determined 
by morphology). Scale bar = 50 µm. Efficiency of transduction in the brain was determined by counting GFP-positive cells in 1 mm2 area of each brain 
section and normalizing the resulting numbers to the average number of CMV treatment for each brain region (e—cortex; f—hippocampus; g—brain 
stem; h—cerebellum). The bar graphs represent relative mean ± SD. Statistical significance was determined using one-way analysis of variance with 
Bonferroni test for multiple comparisons normalized to a control CMV. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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stem region, particularly those areas involved in the motor control 
pathways, when scAAV9-Hb9-GFP vectors were delivered via cis-
terna magna.
DISCUSSION
Previous reports have demonstrated the ability of scAAV9 vectors 
to cross the blood–brain barrier when delivered intravenously.2,31 
Direct administration of scAAV9 to the CSF, coupled with the use of 
a specific promoter, can further target desired cell types within the 
CNS and is of particular interest to neurodegeneration therapeutics, 
where cell-specific expression of a transgene may be required. In 
this study, we examined transduction efficiency of cisterna magna-
delivered scAAV9 expressing GFP under the control of neuron-
specific SYN1, Hb9 enhancer (Hb9e), or Hb9cmv fusion promoters, 
and compared this to the ubiquitous CMV and CAG promoters. We 
have achieved widespread gene delivery throughout the brain and 
spinal cord by delivering scAAV9-GFP into cisterna magna of neo-
natal mice. We have demonstrated that the level of gene expression 
was dependent on the choice of the promoter. The current study 
revealed that Hb9 promoter regulatory sequences derived from 
the promoter of a motor neuron-specific gene were able to target 
expression to the areas of the brain stem, but not the spinal cord, 
while SYN1 promoter offered a uniform neuron-specific transduc-
tion throughout the CNS. The latter finding was consistent with pre-
vious studies using alternative AAV delivery routes.10,20 Moreover, 
we demonstrate the novel applicability of the short Hb9 promoter 
elements for in vitro applications using AAV9 in primary neuron cul-
tures for specific neuronal targeting, where moderate gene expres-
sion levels may be required.
Intracerebrospinal fluid delivery of AAV vectors via cisterna 
magna is a relatively recently established route of delivery in gene 
transfer studies, which has been gaining preference particularly in 
preclinical studies using large animals.11–14 Major advantages of this 
delivery route include: (i) substantially smaller quantity of the vec-
tor required compared to systemic delivery of AAV vectors, which 
directly impacts standard laboratory production of multiple vector 
constructs and large-scale clinical-grade production of the virus; 
and (ii) reduction of viral particles reaching peripheral organs such 
as liver.13,16 Recently published evidence suggests that AAV9, but 
not AAV1 or -5, expressing GFP under the control of the CMV pro-
moter and delivered via cisterna magna leads to the most abundant 
transduction within the cervical and lumbar spinal cord regions of 
mice.11 Consistent with these previous findings, here we observed 
efficient gene transfer in the brain and spinal cord of young mice, 
covering cerebellum, brain stem, hippocampus, and cortices using 
CMV, CAG, and SYN1 promoters. These data show that delivery of 
scAAV9 into the cisterna magna of neonatal mice is an efficient 
delivery route for widespread transduction of CNS regions.
Despite bypassing the blood–brain barrier, cisterna magna route 
of delivery does not offer neuron-specific gene expression due 
to the ability of AAV9 to infect a wide range of cells, an observa-
tion supported by our study and previous reports.11,15,16 Given the 
implication of astrocytes in the pathology of neurodegenerative 
diseases, such as Alzheimer’s disease, spinal muscular atrophy and 
amyotrophic lateral sclerosis,32–35 the high level of non-neuronal cell 
transduction with CMV and CAG promoters, demonstrated in this 
study (Supplementary Figure S4), may be advantageous for those 
disease models. However, when there is a risk of disseminated 
expression of a protein with a potentially toxic function in off-tar-
get cell types and organs, neuron-specific promoters are preferred. 
Hb9cmv and Hb9e promoters, in addition to the well-characterized 
SYN1 promoter,10,20–22 may provide such utility for the AAV9-
mediated therapy targeting neurological diseases, as they confer 
minimal non-neuronal gene expression when used with scAAV9 
background.
Hb9 protein is a transcription factor whose functions have been 
largely attributed to the spinal cord and, in particular, motor neu-
rons.28 Hb9 protein is a known motor neuron marker for neurons 
differentiated from induced pluripotent stem cells36,37; however, 
its role in the brain is not clearly defined. Our results provide novel 
information regarding the activity of the distal enhancer elements 
of Hb9 promoter within the brain stem of postnatal animals, sug-
gesting that scAAV9-Hb9 could be a useful vector for directing gene 
expression selectively to brain stem neurons. However, the virtual 
lack of transduction by the Hb9 distal enhancer elements (Hb9e) at 
other CNS sites suggests that this selectivity would be gained at the 
expense of lower overall expression. While we cannot yet speculate 
about the complete lack of activity of these Hb9 enhancers in adult 
animals, given their weak expression in vitro (Figure 2), Hb9-driven 
GFP expression in living mice may also be below detection thresh-
olds due to the vector doses used in our studies. The presence of 
GFP in the spinal cord driven by other promoters suggests that the 
absence of transduction with the Hb9 promoters in the spinal cord 
(Figure 4) was not due to inadequate delivery following cisterna 
magna administration. Interestingly, Peviani et al.26, have previously 
reported astrocytic and other non-neuronal cell targeting using 
the same Hb9 enhancer sequences in the lentiviral vector platform 
after intraparenchymal delivery directly to the lumbar spinal cord. 
Similarly, we also observed some scattered non-neuronal cell tar-
geting within the brain using both Hb9cmv and Hb9e promoters 
in scAAV9 system, suggesting that this was not exclusively due to 
the presence of the CMVmp sequence. A 1.6 kb pair distal promoter 
region, comprising the two enhancers targeted exclusively neurons 
when delivered via a lentiviral vector into the spinal cord.26 These 
data would suggest that additional sequence elements within the 
distal promoter may also contribute to neuronal specificity; how-
ever, due to the transgene packaging capacity limitation in scAAV 
vectors, using larger promoter fragments would result in inefficient 
gene transfer irrespective of the delivery route. Additional transcrip-
tionally conserved regions within the proximal part of the Hb9 pro-
moter have been identified27 but their applicability in gene therapy 
vectorology is yet to be established. A more comprehensive analy-
sis of Hb9 promoter activity and its expression in diseased neurons 
may be required to be able to speculate whether therapeutic gene 
delivery using Hb9 promoter would be appropriate for neurode-
generative conditions.
In summary, despite the cell-type specificity conferred by a neu-
ronal promoter, gene therapy studies may need to take into account 
the desired levels of therapeutic protein expression, the route of 
delivery and the amount of virus being used. Several clinical trials 
are currently focusing on the surgical delivery of the vectors for neu-
rodegenerative disease, such as anti-Batten’s disease therapy using 
intracranial routes for AAV2-CLN2 administration; whereas intra-
venous delivery is now being adopted as the route of administer-
ing AAV9-SMN vector for spinal muscular atrophy treatment in the 
phase 1/2 trial, with the outcome of this study currently pending.38 
Through the intracisternal route of delivery it is possible to achieve 
a high level of therapeutic gene delivery throughout CNS without 
highly invasive surgical intervention. In addition, cisterna magna 
delivery offers an attractive advantage for viral vector adminis-
tration due to substantial reduction of the disseminated gene 
transfer to the peripheral organs and evasion of the host immune 
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response.13 Combining this approach with sufficient viral genomes 
and targeted promoter constructs will achieve desired specific-
ity tailored to a particular therapeutic gene target. In this way, our 
study represents another step forward towards a targeted design of 
a gene delivery strategy using AAV9 vectors.
MATeRIAlS AND MeTHODS
Plasmid constructs
Plasmid scAAV-CMV-GFP was received from St. Jude Children’s Research 
Hospital (Memphis, TN). To construct the scAAV-GFP transgene plasmid vec-
tors carrying different promoters (Figure 1), the promoter elements were 
amplified as described below and depicted on Figure 1, using the primers 
specified in Table 1, and cloned into scAAV-CMV-GFP cassette replacing 
the original CMV promoter. To generate Hb9 enhancer (Hb9e) and Hb9cmv 
hybrid promoter fused to CMV minimal promoter (mp), Hb9 regulatory ele-
ments of 313 and 120 bp long30 were amplified from pHb9-EGFP expres-
sion vector (Addgene plasmid 16275 (ref. 29); Addgene, Cambridge, MA) 
containing the full Hb9 promoter sequence and cloned between restriction 
sites as indicated in Figure 1a. Full CMV promoter and CMVmp were derived 
from pAAV-MCS (Stratagene, Stockport, UK). Human synapsin 1 promoter 
was amplified from pAAV-SYN1-RFP, a gift from Edward Callaway (Addgene 
plasmid 22907).21 CAG promoter, composed of chicken β-actin promoter 
and CMV enhancer, was amplified from pCAGGS plasmid obtained from the 
Belgian Coordinated Collection of Microorganisms.39 Standard cloning pro-
cedures for DNA extraction and production of the large-scale plasmids were 
followed using QIAGEN kits following the manufacturer’s instructions.
Large-scale production of scAAV9
Stocks of scAAV9-GFP were produced by transfecting human embryonic kid-
ney HEK293T cells and purifying using iodixanol gradient purification method. 
Briefly, HEK293T cells in 15 cm dishes were transfected with packaging plas-
mids pHelper (Stratagene; Stockport, UK), pAAV2/9 (kindly provided by 
J.Wilson, University of Pennsylvania) and one of the transgene plasmids scAAV-
GFP at 2:1:1 ratio, respectively, using polyethylenimine (1 mg/ml) in serum-free 
Dulbecco’s modified Eagle’s medium. At 4 days post-transfection, supernatant 
containing cell-released virus was harvested, treated with benzonase (10 
unit/ml; Sigma, Poole, UK) for 2 hours at 37 °C and concentrated to equal to 
approximately 24 ml using Amicon Ultra-15 Centrifugal 100K Filters (Millipore, 
Watford, UK). Iodixanol gradient containing 15, 25, 40, and 54% iodixanol solu-
tion in phosphate-buffered saline (PBS)/1 mmol/l MgCl2/2.5 mmol/l KCl and 
virus solution was loaded and centrifuged at 69,000 revolutions per minute for 
90 minutes at 18 °C. After ultracentifugation, the virus fractions were visualized 
on a 10% polyacrylamide gel, stained using SYPRO Ruby (Life Technologies, 
Paisley, UK) according to the manufacturer’s guidelines. The highest purity 
fractions (identified by the presence of the three bands corresponding to VP1, 
VP2, and VP3) were pooled and concentrated further in the final formulation 
buffer consisting of PBS supplemented with an additional 35 mmol/l NaCl40 
using Amicon Ultra-15 Centrifugal 100K filters. Viral titers were determined by 
quantitative PCR assays using primers directed against GFP and a linearized 
scAAV-CMV-GFP vector as a standard curve.
In vitro AAV transduction of the embryonic mouse spinal cord 
neurons
A pregnant female wild-type C57bl/6 mouse was sacrificed at 13 days of ges-
tation (E13) using Schedule 1 method in accordance with Home Office UK 
regulations. Embryos were removed, and the spinal cords were dissected out. 
The cells were dissociated by trypsinization and trituration, pooled together 
and plated onto 10 mm glass coverslips precoated with 50 µg/ml poly-D-
ornithine hydrobromide and 2.5 µg/ml laminin (Sigma, Poole, UK) at a den-
sity of 60,000 cells per coverslip. Cells were maintained in Neurobasal media 
supplemented with 0.5% penicillin/streptomycin, 2 mmol/l L-glutamine, 2% 
horse serum, and 2% B27 supplement. 50% media was changed every 48 
hours. Transduction with scAAV9-GFP vectors was carried out at 40–48 hours 
after initial plating (2 days in vitro) by applying up to 5 × 109 vg per cell mono-
layer for 7 days before fixing in 4% paraformaldehyde. Cells were monitored 
on a daily basis, as GFP fluorescence was developed.
Immunocytochemistry
Transduced or mock-treated cells were fixed in 4% paraformaldehyde, per-
meabilized in 0.2% Triton X-100/PBS (PBS-Tx), blocked with 10% normal 
goat serum (NGS) in PBS-Tx and then incubated with primary antibodies 
in a single antibody staining assay against neuronal tubulin marker MAP2 
(1:1,000; Sigma), motor neuron markers Islet-1 (1:1,000; Abcam, Cambridge, 
UK) or astrocyte marker GFAP (1:1,000; Sigma) diluted in 2% NGS/PBS-Tx 
overnight at 4 °C. The following day the cells were counter-stained with sec-
ondary Alexa-Fluor conjugated antibodies for 1 hour at room temperature, 
and washed in PBS between the incubations. Finally, coverslips were stained 
with Hoechst stain (1:2,000; Sigma) to visualize the nuclei and mounted 
onto a slide using FluoroMount media (Sigma). The images were captured 
on Leica confocal laser-scanning microscope using 63× oil lens and appro-
priate optical zoom, and processed using LAS AF Lite and ImageJ softwares.
Quantification of in vitro GFP fluorescence and statistical analysis
To quantify GFP-positive cells and intensity of GFP fluorescence, images were 
captured on InCell imager (GE Healthcare, Chalfont St Giles, UK) using 20× 
magnification. For determining transduction efficiencies using automated 
Table 1 Primers used in construction of scAAV-GFP plasmids with different promoter elements
Primer name Sequence Promoter construct
Hb9A-Mlu For GCGGCGGACGCGTTGAATAAATTTAAGCAGG Hb9cmv and Hb9e
Hb9A-Bgl Rev GTATGCAGATCTAGCCCCATCCCCCTTCAAT Hb9cmv and Hb9e
Hb9B-Bgl For GCGCGGAGATCTAGAGTGGTTAGCTGATGAAT Hb9cmv and Hb9e
Hb9B-Age Rev CGTCTTACCGGTTCTAATCAG CCTGCCTAGCT Hb9cmv
Hb9B-Eco Rev CGTCTTGAATTCTCTAATCAG CCT GCCTAGCT Hb9e
CMVmp-Age For GTAATGAACCGGTTAGGCGTGTACGGTGGGA Hb9cmv
CMV Mlu For GGCCGGACGCGTGGA GCTAGTTATTAATAG CMV
CMV-Eco Rev ATTCGTGAA TTCAGG CTGGATCGGTCCCGGT Hb9cmv and CMV
SYN1-Mlu For ACAATGACGCGTCTGCAGAGGGCCCTGCGTATG SYN1
SYN1-Eco Rev ATCATAGAATTCGCCGCAGCGCAGATGGTCGCG SYN1
CAG Mlu For ATTGGCACGCGTGACATTGATTATTGACTA CAG
CAG Eco Rev ATTATTGAATTCCGCCCGCCGCGCGCTTCG CAG
Primer hybridization sites are underlined. Sequences are demonstrated as 5′→3′. Restriction sites are highlighted in bold. Hb9A and B refer to 313 and 125 bp 
fragments, respectively. For, forward primer; Rev, reverse primer.
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InCell Developer Software (GE Healthcare) with a gray level range of 
0-65535, up to 3,000 cells were counted. Background GFP fluorescence was 
determined on cell-free area of each treatment or mock-treated cells, and 
the GFP-positive cell numbers were normalized to above the background 
values. In order to determine and compare GFP expression intensities for 
each treatment, the gray values in the GFP-positive cells above the back-
ground were averaged. The collected data represent mean values based on 
triplicate treatments. Statistical analysis of in vitro AAV transduction data was 
performed by one-way analysis of variance in GraphPad Prism (version 6.05) 
with each promoter representing a separate group. Multiple comparisons 
between the means were done using Tukey’s multiple comparison test with 
95% confidence interval.
In vivo scAAV9 transduction of wild-type neonatal mice
All experiments involving mice were conducted according to the Animal 
(Scientific Procedures) Act 1986, under Project License 40/3739 and 
approved by the University of Sheffield Ethical Review Sub-Committee, and 
the UK Animal Procedures Committee (London, UK). The UK Home Office 
code of practice for the housing and care of animals used in scientific pro-
cedures was followed according to Animal (Scientific Procedures) Act 1986. 
Animals were maintained in a controlled facility in a 12-hour dark/12-hour 
light cycle, a standardized room temperature of 21 °C, with free access to 
food and water.
For scAAV9 delivery into the CSF via cisterna magna, 15 wild-type C57BL/6 
mice (n = 3 per group) at postnatal day 1 were anesthetized in an induc-
tion chamber using 5% isoflurane and oxygen at 3 l/minute before being 
placed on a red transilluminator (Philips Healthcare “Wee Sight”—product 
no. 1017920) with their head tilted slightly forward and nose attached to 
an anesthetic supply. Anesthesia was maintained with 2% isoflurane and 
oxygen at 0.3 l/minute. A 33-gauge needle attached to a Hamilton syringe 
and peristaltic pump was lowered approximately 1 mm into the cisterna 
magna area using stereotaxic apparatus at an angle of 45 degrees, and 1 µl 
of viral solution (1 × 1010 vg/µl) was injected at a rate of 1 µl/minute. An equal 
volume of PBS/35 mmol/l NaCl was used as a control solution. Three weeks 
after virus injection, the animals were terminally anesthetized with an intra-
peritoneal injection of an overdose of sodium pentobarbital, and perfused 
transcardially with PBS/heparin solution, followed by 4% paraformaldehyde 
(PFA) in PBS. Brains and spinal cords were postfixed in 4% PFA overnight at 
4 °C, and then subjected to two rounds of cryoprotection by incubating the 
tissue in 30% sucrose/PBS solution for 24–48 hours at 4 °C.
Immunohistochemistry of CNS tissue
For immunohistochemistry analysis, the tissues were embedded in O.C.T. 
embedding matrix, and 40-µm-thick brain sections and 25-µm-thick spinal 
cord sections were cut on a cryostat at −22 °C free-floating or onto a slide, 
respectively. Brain sections or spinal cord sections were washed twice with 
PBS, permeabilized in PBS/0.3% Triton X-100, blocked with 10% NGS in 
PBS/0.3% Triton X-100 solution for up to 3 hours, and incubated with primary 
antibodies diluted in 2% NGS in PBS/0.15% Triton X-100 overnight. Primary 
antibodies were a combination of rabbit anti-GFP (1:500; Life Technologies) 
with either of the following mouse antibodies: anti-NeuN (1:300; Millipore, 
Watford, UK) or anti-Calcitonin gene related peptide (CGRP) (1:500; Sigma). 
The following day, the sections were washed in PBS four times for up to 2 hours 
and incubated with secondary antibodies Alexa-Fluor anti-mouse 568 or anti-
rabbit 488 (Life Technologies) diluted in 5% NGS/PBS for 1 hour. For visualizing 
nuclei, 1:2500 Hoechst stain (Sigma) in PBS was used. Images were captured 
on Leica confocal microscope using 40× oil lens and optical zoom, and were 
processed using LAS AF Lite software and ImageJ. Low-magnification images 
of the spinal cord sections were captured on Leica confocal microscope using 
10× dry lens and 488 nm wavelength (FITC channel) only. Low-magnification 
images of the brain sections were captured using 2× and 4× lens on a Nikon 
fluorescent microscope.
Quantification of in vivo gene transfer and statistical analysis
For quantification of GFP-positive cells in the ventral horns of lumbar and 
cervical spinal cord sections, a Nikon fluorescent microscope with 20× 
lens was used to capture an image of the ventral horn from three sections 
(approximately 300 µm apart) of lumbar and cervical spinal cord per animal. 
The sum of GFP-positive cells in the three ventral horns per animal was used 
for analysis. The data was normalized to the CMV promoter in the cervical 
group region. Statistical analysis on the spinal cord counts was performed 
by two-way analysis of variance using GraphPad prism, with region and 
promoter as the two independent variables. For spinal cord data set, simple 
effects of promoters (CMV, CAG, and SYN1 only) were compared within each 
region (cervical or lumbar) using Tukey’s multiple comparisons test to a con-
trol group CMV.
For quantification of the brain sections, wide-field fluorescence images 
were captured using a 10× lens. In each of the four chosen brain areas (cer-
ebellum, hippocampal formation, midbrain, and motor cortex), one image 
per region per animal (representing a region of 1 mm2) was captured and 
used for counting. The numbers of GFP-positive cells were counted manually 
with the assistance of ImageJ software (Cell Counter plug-in), by an observer 
blinded to vector treatment. The cell counts were normalized to the average 
of scAAV9-CMV-GFP-treated group for each brain region. Statistical analysis 
for the brain counts was performed using one-way analysis of variance with 
Bonferroni’s multiple comparison test to CMV control.
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